Nu-Med Plus Inc (NUMD) is a pre-revenue medical device and pharmaceutical development company working to develop nitric oxide delivery systems and proprietary nitric oxide formulations for human medical use. The company has generated no product revenue, as all product development was suspended pending receipt of a capital infusion, per its 10-K filed April 15, 2026 for the fiscal year ended December 31, 2025. Nu-Med's intended products include a nitric oxide gas dispensing unit and a proprietary compound formulation designed to generate nitric oxide on demand. Both require FDA approval before any U.S. sales can occur. The only FDA-approved use of inhaled nitric oxide as of the filing date is treatment of hypoxia in premature infants and newborns. Nu-Med's corporate office is located in Port Jefferson, NY, with an R&D facility in West Jordan, UT. The company faces competition from multinational medical device and pharmaceutical companies with substantially greater financial resources. Leadership includes CEO and Director William Hayde (age 61) and CFO and Director Keith Merrell (age 80).

Revenue model

Nu-Med Plus has no current revenue. The company is pre-commercial, with product development suspended as of the fiscal year ended December 31, 2025, pending external capital. No revenue model is operational.

Products and services

Proprietary nitric oxide gas formulation designed to generate nitric oxide on demand; nitric oxide dispensing unit intended for medical delivery. Both products require FDA approval prior to any commercial sales. Development is suspended pending funding, per the 10-K filed April 15, 2026.

Customers and end markets

Intended end markets include treatment of hypoxia in premature infants and newborns (the only FDA-approved nitric oxide indication as of the filing), with potential future applications in COPD, bacterial infections, tuberculosis, non-healing wounds, and other conditions pending FDA approval. No commercial customers as of the fiscal year ended December 31, 2025.

Value-chain role

Early-stage developer of nitric oxide drug formulations and delivery devices. The company is positioned upstream of manufacturing and distribution, with no manufacturing, sales, or distribution operations currently active.

Geographic exposure

United States. Corporate office in Port Jefferson, NY; R&D facility in West Jordan, UT, as disclosed in the 10-K filed April 15, 2026.

Source: SEC 10-K, filed 2026-04-15

Industry: Surgical & Medical Instruments & Apparatus